Legal Opinion
Bristol-Myers Squibb Company v. Teva Pharmaceuticals USA, Inc.
Court of Appeals for the Federal Circuit
Decided June 12, 2014No. 2013-1306PublishedCited by 49 opinions
1Opinion of the Court
CHEN, Circuit Judge.
This patent infringement case concerns a drug for the treatment of hepatitis B. After a four-day bench trial, the United States District Court for the District of Delaware found claim 8 of U.S. Patent No. 5,206,244 (’244 patent) invalid as obvious. We affirm the district court’s invalidity judgment for the reasons that follow.
I
Appellant Bristol-Myers Squibb Co. (BMS) owns the '244 patent. Claim 8 of the '244 patent is directed to a nucleoside analog composed of two regions: a carbo-cyclic ring and a guanine base. Nucleo-side analogs are manmade compounds designed to mimic…
2Cases cited29 opinions
- Graham v. John Deere Co. of Kansas CitySupreme Court of the United States · 1966
- KSR International Co. v. Teleflex Inc.Supreme Court of the United States · 2007
- Stratoflex, Inc. v. Aeroquip CorporationCourt of Appeals for the Federal Circuit · 1983
- The Standard Oil Company, Appellant/cross-Appellee v. American Cyanamid Company, Appellee/cross-AppellantCourt of Appeals for the Federal Circuit · 1985
- Pfizer, Inc. v. Apotex, Inc.Court of Appeals for the Federal Circuit · 2007
24 more not listed; retrieve them via the Exa API.
3Cited by49 opinions
- Arctic Cat Inc. v. Bombardier Recreational Products Inc.Court of Appeals for the Federal Circuit · 2017
- Forest Laboratories, LLC v. Sigmapharm Laboratories, LLCCourt of Appeals for the Federal Circuit · 2019
- Cadence Pharmaceuticals Inc. v. Exela Pharma Sciences LLCCourt of Appeals for the Federal Circuit · 2015
- Merck & Cie v. Gnosis S.P.A.Court of Appeals for the Federal Circuit · 2015
- Sanofi-Aventis U.S., LLC v. Fresenius Kabi USA, LLCCourt of Appeals for the Federal Circuit · 2019
44 more not listed; retrieve them via the Exa API.